Three Data Center Stocks to Buy Emerge as Promising Ways to Profit
Three data center stocks to buy offer investors an opportunity to profit from growing collation services providers that are supporting growth in the information technology (IT) world. The three data center stocks to buy are expected to “outperform”…
Three data center stocks to buy offer investors an opportunity to profit from growing collation services providers that are supporting growth in the information technology (IT) world.
The three data center stocks to buy are expected to “outperform” the market’s overall performance, according to ISI Evercore, an investment firm that recently initiated coverage of the industry. ISI Evercore’s coverage will feature U.S.-headquartered colocation services providers as the industry composes a total available market of roughly $37 billion, fueled by a compound annual growth rate (CAGR) of 7%.
Given the foundational, but often underappreciated role of multi-tenant data centers as key cogs within a hybrid IT world, ISI Evercore sees a fertile field for investors. The combination of “exponential data creation,” traffic growth and digital transformation initiatives across enterprise, cloud, service providers, public sector and demand for optimized IT performance should drive sector growth, ISI Evercore wrote in its research note.
Three Data Center Stocks to Buy Can Be Purchased Through REITs
Plus, the real estate investment trust (REIT) structure makes data center stocks a unique asset class that should appeal to a broad range of investors, according to ISI Evercore. Despite concerns about the threat of public cloud and commoditization of data center services, ISI Evercore forecasts hyperscale growth.
“In addition, there are opportunities for companies to differentiate via interconnection and adjacent offerings such as managed services,” ISI Evercore wrote. Within this industry, we favor companies that have global scale and the ability to attach value-add services.”
Equinix Rates as One of the Three Data Center Stocks to Buy
Equinix (NASDAQ: EQIX), of Redwood City, California, is a Silicon Valley, multi-tenant data center provider that allows competing networks to connect and share data traffic securely. The name Equinix was chosen to reflect the company’s focus on equality, neutrality and internet exchange.
ISI Evercore ranked Equinix as one of three data center stocks that the investment firm expects to outperform the market. Equinix received a target price of $950 from ISI Evercore.
Digital Realty Trust Secures Spot Among Three Data Center Stocks to Buy
San Francisco’s Digital Realty Trust, Inc. (NYSE: DLR) supports data center, colocation and interconnection strategies of customers worldwide, ranging from cloud and information technology services, communications and social networking. It also serves financial services, manufacturing, energy, health care and consumer markets.
ISI Evercore gave Digital Realty Trust, Inc. (DLR) an outperform rating and a target price of $180.
CyrusOne Captures Slot Among the Three Data Center Stocks to Buy
Dallas-based CyrusOne, Inc. (NASDAQ: CONE) has a wide portfolio that includes more than 40 enterprise-class facilities across three continents, and more than 4 million square feet of total net rentable square footage. Recent developments at CONE could create near-term catalysts for the stock, ISI Evercore wrote.
Customers lower short and long-term capital and operating costs by designing customized data center solutions tailored to a company’s current and future IT needs. Those customers also can reallocate precious IT resources back to driving innovation and growth for their core business.
ISI Evercore wrote positively about the recent return of CONE’s co-founder as chief executive officer, warranting an “attractive valuation” that creates a “tactical buying opportunity” in the stock. The investment bank gave the stock an “outperform” rating and a target price of $100 per share.
Three Data Center Stocks to Buy Omit CoreSite Realty Corp.
ISI Evercore added Denver’s CoreSite Realty Corporation (COR) as a fourth data center stock that it included in its new coverage but rated it as an “in line” prospect, not one of the sector’s three stocks that it predicts will “outperform” the market. The stock appears “fairly valued” at current levels with a target price of $154, the investment firm wrote.
The company uses a cloud, interconnection and colocation platform to design, plan and implement its hybrid, multi-cloud IT solution. With CoreSite, businesses have optionality to allow cost-effective growth within network-dense edge markets.
Growth drivers for the sector include data increases and creation; demand for digital transformation through optimized IT infrastructures, flexibility and scalability modularity; migration toward a hybrid IT architecture; and adoption of distributed IT architectures becoming the norm, ISI Evercore wrote. In addition, vendors can differentiate their offering with innovation via value-add services to achieve higher pricing and lower commoditization risk.
Also expect the public cloud to be a net positive for the colocation industry, ISI Evercore continued. And scale will matter as colocation companies with a global presence benefit from their increased geographic flexibility amid continued industry consolidation.
Pension Fund Chief Offers Alternative toThree Data Center Stocks to Buy
“Data centers and cell towers have been a focus of my preferred REIT mutual fund, Cohen & Steers Realty Shares (CSRSX), for a number of years,” said Bob Carlson, who leads the Retirement Watch investment newsletter. “They’ve been among the top sectors in the fund for some time and appear likely to remain so.”
Cohen & Steers identifies these sectors with those that will benefit from major changes that are likely to persist for some time, continued Carlson, who serves as chairman of the Board of Trustees of Virginia’s Fairfax County Employees’ Retirement System with more than $4 billion in assets. The sectors benefit from the increased use of technology, especially mobile technology, he added.
“Data centers benefit from the move of data and computing activities to the cloud instead of servers and hard drives residing at a business or home,” Carlson said.
The top holdings in these sectors for Cohen & Steers recently were American Tower Corporation (NYSE: AMT), Equinix, CyrusOne, Digital Realty Trust, Crown Castle International (NYSE: CCI) and SBA Communications (NASDAQ: SBAC). Investors who want to use a little leverage to benefit from these and other REITs can invest in the closed-end fund, Quality Income Realty (RQI). It has a leverage ratio of about 24% and a recent distribution rate of 7.42%, Carlson added.
As one of his Income Multiplier picks, Boston-based American Tower has produced an average return of 16% during the past five years. The company is a real estate investment trust and an owner and operator of wireless and broadcast communications infrastructure in several countries worldwide.
Paul Dykewicz meets with Wall Street veteran Jim Woods, editor of Intelligence Report.
COVID-19’s Delta Variant Will Not Stop Three Data Center Stocks to Buy
The highly transmissible Delta variant of COVID-19 has produced a reduced number of cases and deaths in the United States lately but it remains a concern for public health experts who keep urging increased vaccinations and booster shots, as well as mask wearing. The Centers for Disease Control and Prevention (CDC) specifically has blamed the variant for unleashing a resurgence of cases and deaths earlier in the fall.
However, the variant is leading to an jump in the number of people vaccinated from COVID-19. As of Nov. 2, 221,961,370 people, or 66.9% of the U.S. population, have received at least one dose of a COVID-19 vaccine, the CDC reported. The fully vaccinated total 192,726,406 people, or 58.1%, of the U.S. population, according to the CDC.
COVID-19 deaths worldwide, as of Nov. 2, topped the 5 million mark by reaching 5,011,786, according to Johns Hopkins University. Worldwide COVID-19 cases totaled 247,447,923, as of that date.
U.S. COVID-19 cases, as of Nov. 2, reached 46,140,129 and caused 748,173 deaths. America has the dreaded distinction as the country with the most COVID-19 cases and deaths.
The three data center stocks to buy can help investors to profit amid the pandemic and ride a technology wave that is sweeping the world.
Paul Dykewicz, www.pauldykewicz.com, is an accomplished, award-winning journalist who has written for Dow Jones, the Wall Street Journal, Investor’s Business Daily, USA Today, the Journal of Commerce, Seeking Alpha, GuruFocus and other publications and websites. Paul, who can be followed on Twitter @PaulDykewicz, is the editor of StockInvestor.com and DividendInvestor.com, a writer for both websites and a columnist. He further is editorial director of Eagle Financial Publications in Washington, D.C., where he edits monthly investment newsletters, time-sensitive trading alerts, free e-letters and other investment reports. Paul previously served as business editor of Baltimore’s Daily Record newspaper. Paul also is the author of an inspirational book, “Holy Smokes! Golden Guidance from Notre Dame’s Championship Chaplain,” with a foreword by former national championship-winning football coach Lou Holtz. The book is great as a gift and is endorsed by Joe Montana, Joe Theismann, Ara Parseghian, “Rocket” Ismail, Reggie Brooks, Dick Vitale and many others. Call 202-677-4457 for special pricing.
New York Jets quarterback Aaron Rodgers and former Minnesota governor and professional wrestler Jesse Ventura are among the potential running mates for independent presidential candidate Robert F. Kennedy Jr., the New York Times reported on March 12.
Citing “two people familiar with the discussions,” the New York Times wrote that Mr. Kennedy “recently approached” Mr. Rodgers and Mr. Ventura about the vice president’s role, “and both have welcomed the overtures.”
Mr. Kennedy has talked to Mr. Rodgers “pretty continuously” over the last month, according to the story. The candidate has kept in touch with Mr. Ventura since the former governor introduced him at a February voter rally in Tucson, Arizona.
Stefanie Spear, who is the campaign press secretary, told The Epoch Times on March 12 that “Mr. Kennedy did share with the New York Times that he’s considering Aaron Rodgers and Jesse Ventura as running mates along with others on a short list.”
Ms. Spear added that Mr. Kennedy will name his running mate in the upcoming weeks.
Former Democrat presidential candidates Andrew Yang and Tulsi Gabbard declined the opportunity to join Mr. Kennedy’s ticket, according to the New York Times.
Mr. Kennedy has also reportedly talked to Sen. Rand Paul (R-Ky.) about becoming his running mate.
Last week, Mr. Kennedy endorsed Mr. Paul to replace Sen. Mitch McConnell (R-Ky.) as the Senate Minority Leader after Mr. McConnell announced he would step down from the post at the end of the year.
CNN reported early on March 13 that Mr. Kennedy’s shortlist also includes motivational speaker Tony Robbins, Discovery Channel Host Mike Rowe, and civil rights attorney Tricia Lindsay. The Washington Post included the aforementioned names plus former Republican Massachusetts senator and U.S. Ambassador to New Zealand and Samoa, Scott Brown.
In April 2023, Mr. Kennedy entered the Democrat presidential primary to challenge President Joe Biden for the party’s 2024 nomination. Claiming that the Democrat National Committee was “rigging the primary” to stop candidates from opposing President Biden, Mr. Kennedy said last October that he would run as an independent.
This year, Mr. Kennedy’s campaign has shifted its focus to ballot access. He currently has qualified for the ballot as an independent in New Hampshire, Utah, and Nevada.
Mr. Kennedy also qualified for the ballot in Hawaii under the “We the People” party.
In January, Mr. Kennedy’s campaign said it had filed paperwork in six states to create a political party. The move was made to get his name on the ballots with fewer voter signatures than those states require for candidates not affiliated with a party.
The “We the People” party was established in five states: California, Delaware, Hawaii, Mississippi, and North Carolina. The “Texas Independent Party” was also formed.
A statement by Mr. Kennedy’s campaign reported that filing for political party status in the six states reduced the number of signatures required for him to gain ballot access by about 330,000.
Ballot access guidelines have created a sense of urgency to name a running mate. More than 20 states require independent and third-party candidates to have a vice presidential pick before collecting and submitting signatures.
Like Mr. Kennedy, Mr. Ventura is an outspoken critic of COVID-19 vaccine mandates and safety.
Mr. Ventura, 72, gained acclaim in the 1970s and 1980s as a professional wrestler known as Jesse “the Body” Ventura. He appeared in movies and television shows before entering the Minnesota gubernatorial race as a Reform Party headliner. He was a longshot candidate but prevailed and served one term.
Former pro wrestler Jesse Ventura in Washington on Oct. 4, 2013. (Brendan Smialowski/AFP via Getty Images)
In an interview on a YouTube podcast last December, Mr. Ventura was asked if he would accept an offer to run on Mr. Kennedy’s ticket.
“I would give it serious consideration. I won’t tell you yes or no. It will depend on my personal life. Would I want to commit myself at 72 for one year of hell (campaigning) and then four years (in office)?” Mr. Ventura said with a grin.
Mr. Rodgers, who spent his entire career as a quarterback for the Green Bay Packers before joining the New York Jets last season, remains under contract with the Jets. He has not publicly commented about joining Mr. Kennedy’s ticket, but the four-time NFL MVP endorsed him earlier this year and has stumped for him on podcasts.
The 40-year-old Rodgers is still under contract with the Jets after tearing his Achilles tendon in the 2023 season opener and being sidelined the rest of the year. The Jets are owned by Woody Johnson, a prominent donor to former President Donald Trump who served as U.S. Ambassador to Britain under President Trump.
Since the COVID-19 vaccine was introduced, Mr. Rodgers has been outspoken about health issues that can result from taking the shot. He told podcaster Joe Rogan that he has lost friends and sponsorship deals because of his decision not to get vaccinated.
Quarterback Aaron Rodgers of the New York Jets talks to reporters after training camp at Atlantic Health Jets Training Center in Florham Park, N.J., on July 26, 2023. (Rich Schultz/Getty Images)
Earlier this year, Mr. Rodgers challenged Kansas City Chiefs tight end Travis Kelce and Dr. Anthony Fauci to a debate.
Mr. Rodgers referred to Mr. Kelce, who signed an endorsement deal with vaccine manufacturer Pfizer, as “Mr. Pfizer.”
Dr. Fauci served as director of the National Institute of Allergy and Infectious Diseases from 1984 to 2022 and was chief medical adviser to the president from 2021 to 2022.
When Mr. Kennedy announces his running mate, it will mark another challenge met to help gain ballot access.
“In some states, the signature gathering window is not open. New York is one of those and is one of the most difficult with ballot access requirements,” Ms. Spear told The Epoch Times.
“We need our VP pick and our electors, and we have to gather 45,000 valid signatures. That means we will collect 72,000 since we have a 60 percent buffer in every state,” she added.
The window for gathering signatures in New York opens on April 16 and closes on May 28, Ms. Spear noted.
“Mississippi, North Carolina, and Oklahoma are the next three states we will most likely check off our list,” Ms. Spear added. “We are confident that Mr. Kennedy will be on the ballot in all 50 states and the District of Columbia. We have a strategist, petitioners, attorneys, and the overall momentum of the campaign.”
The SNF Institute for Global Infectious Disease Research announces new advisory board
From identifying the influenza virus that caused the pandemic of 1918 to developing vaccines against pneumococcal pneumonia and bacterial meningitis in…
From identifying the influenza virus that caused the pandemic of 1918 to developing vaccines against pneumococcal pneumonia and bacterial meningitis in the 1970s, combating infectious disease has a rich history at Rockefeller. That tradition continues as the Stavros Niarchos Foundation Institute for Global Infectious Disease Research at Rockefeller University (SNFiRU) caps a successful first year with the establishment of a new advisory board.
Credit: Lori Chertoff/The Rockefeller University
From identifying the influenza virus that caused the pandemic of 1918 to developing vaccines against pneumococcal pneumonia and bacterial meningitis in the 1970s, combating infectious disease has a rich history at Rockefeller. That tradition continues as the Stavros Niarchos Foundation Institute for Global Infectious Disease Research at Rockefeller University (SNFiRU) caps a successful first year with the establishment of a new advisory board.
This international advisory board was created in part to give guidance on how to best use SNFiRU’s resources, as well as bring forward innovative ideas concerning new avenues of research, public education, community engagement, and partnership projects.
SNFiRU was established to strengthen readiness for and response to future health crises, building on the scientific advances and international collaborations forged in the context of the COVID-19 pandemic. Launched with a $75 million grant from the Stavros Niarchos Foundation (SNF) as part of its Global Health Initiative (GHI), the institute provides a framework for international scientific collaboration to foster research innovations and turn them into practical health benefits.
SNFiRU’s mission is to better understand the agents that cause infectious disease and to lower barriers to treatment and prevention globally. To speed this work, the institute launched numerous initiatives in its inaugural year. For instance, SNFiRU awarded 31 research projects in 29 different Rockefeller laboratories for over $5 million to help get collaborative new research efforts off the ground. SNFiRU also supports the Rockefeller University Hospital, where clinical studies are conducted, and brought on board its first physician-scientist through Rockefeller’s Clinical Scholars program. “One of the surprises was the scope of interest from Rockefeller scientists in using their talents to tackle important infectious disease problems,” says Charles M. Rice, Maurice R. and Corinne P. Greenberg Professor in Virology at Rockefeller and director of SNFiRU. “The research topics range from the biology of infectious agents to the dynamics of the immune response to pathogens, and also include a number of infectious disease-adjacent studies.”
In the past 12 months, SNFiRU often brought together scientists studying different aspects of infectious disease as a way to spur new collaborations. In addition to hosting its first annual day-long symposium, SNFiRU initiated a Young Scientist Forum for students and post-doctoral fellows to meet regularly, facilitating cross-laboratory thinking. A bimonthly seminar series has also been established on campus.
Another aim of SNFiRU is to develop relationships with community-based organizations, as well as design and participate in community-engaged research, with a focus on low-income and minority communities. To that end, SNFiRU is helping develop a research project on Chagas disease, a tropical parasitic infection prevalent in Latin America that can cause congestive heart failure and gastrointestinal complications if left untreated. The project will bring together clinicians practicing at health centers in New York, Florida, Texas, and California and basic scientists from multiple institutions to help the communities that are most impacted.
“The SNFiRU international advisory board convenes globally recognized leaders with distinguished biomedical expertise, unrivalled experience in pandemic preparedness and response, and a shared commitment to translating scientific advancements into equitably distributed benefits in real-world settings,” says SNF Co-President Andreas Dracopoulos. “The advisory board will advance the institute’s indispensable mission, which SNF is proud to support as a key part of our Global Health Initiative, and we look forward to seeing breakthroughs in the lab drive better outcomes in lives around the globe.”
The new advisory board will hold its first meeting on April 11th, 2024, following the second annual SNF Institute for Global Infectious Disease Research Symposium at Rockefeller.
Its members are: Rafi Ahmed of Emory University School of Medicine, Cori Bargmann of The Rockefeller University, Yasmin Belkaid of the Pasteur Institute, Anthony S. Fauci, the former director of the National Institute of Allergy and Infectious Diseases, Peter Hotez of Baylor College of Medicine and Texas Children’s Hospital Center for Vaccine Development, Esper Kallas of of the Butantan Institute, Sharon Lewin of the University of Melbourne Doherty Institue, Carl Nathan of Weill Cornell Medicine, Rino Rappuoli of Fondazione Biotecnopolo di Siena and University of Siena, and Herbert “Skip” Virgin of Washington University School of Medicine and UT Southwestern Medical Center.
Congress’ failure so far to deliver on promise of tens of billions in new research spending threatens America’s long-term economic competitiveness
A deal that avoided a shutdown also slashed spending for the National Science Foundation, putting it billions below a congressional target intended to…
Federal spending on fundamental scientific research is pivotal to America’s long-term economic competitiveness and growth. But less than two years after agreeing the U.S. needed to invest tens of billions of dollars more in basic research than it had been, Congress is already seriously scaling back its plans.
A package of funding bills recently passed by Congress and signed by President Joe Biden on March 9, 2024, cuts the current fiscal year budget for the National Science Foundation, America’s premier basic science research agency, by over 8% relative to last year. That puts the NSF’s current allocation US$6.6 billion below targets Congress set in 2022.
And the president’s budget blueprint for the next fiscal year, released on March 11, doesn’t look much better. Even assuming his request for the NSF is fully funded, it would still, based on my calculations, leave the agency a total of $15 billion behind the plan Congress laid out to help the U.S. keep up with countries such as China that are rapidly increasing their science budgets.
Our data shows how underfunding basic research, especially in high-priority areas, poses a real threat to the United States’ role as a leader in critical technology areas, forestalls innovation and makes it harder to recruit the skilled workers that high-tech companies need to succeed.
A promised investment
Less than two years ago, in August 2022, university researchers like me had reason to celebrate.
The CHIPS act authorized US$81 billion for the agency, promised to double its budget by 2027 and directed it to “address societal, national, and geostrategic challenges for the benefit of all Americans” by investing in research.
But there was one very big snag. The money still has to be appropriated by Congress every year. Lawmakers haven’t been good at doing that recently. As lawmakers struggle to keep the lights on, fundamental research is quickly becoming a casualty of political dysfunction.
Research’s critical impact
That’s bad because fundamental research matters in more ways than you might expect.
For instance, the basic discoveries that made the COVID-19 vaccine possible stretch back to the early 1960s. Such research investments contribute to the health, wealth and well-being of society, support jobs and regional economies and are vital to the U.S. economy and national security.
Lagging research investment will hurt U.S. leadership in critical technologies such as artificial intelligence, advanced communications, clean energy and biotechnology. Less support means less new research work gets done, fewer new researchers are trained and important new discoveries are made elsewhere.
Businesses nationwide thrive by selling the goods and services – everything from pipettes and biological specimens to notebooks and plane tickets – that are necessary for research. Those vendors include high-tech startups, manufacturers, contractors and even Main Street businesses like your local hardware store. They employ your neighbors and friends and contribute to the economic health of your hometown and the nation.
Nearly a third of the $10 billion in federal research funds that 26 of the universities in our consortium used in 2022 directly supported U.S. employers, including:
A Detroit welding shop that sells gases many labs use in experiments funded by the National Institutes of Health, National Science Foundation, Department of Defense and Department of Energy.
A Dallas-based construction company that is building an advanced vaccine and drug development facility paid for by the Department of Health and Human Services.
More than a dozen Utah businesses, including surveyors, engineers and construction and trucking companies, working on a Department of Energy project to develop breakthroughs in geothermal energy.
When Congress shortchanges basic research, it also damages businesses like these and people you might not usually associate with academic science and engineering. Construction and manufacturing companies earn more than $2 billion each year from federally funded research done by our consortium’s members.
A lag or cut in federal research funding would harm U.S. competitiveness in critical advanced technologies such as artificial intelligence and robotics.Hispanolistic/E+ via Getty Images
Jobs and innovation
Disrupting or decreasing research funding also slows the flow of STEM – science, technology, engineering and math – talent from universities to American businesses. Highly trained people are essential to corporate innovation and to U.S. leadership in key fields, such as AI, where companies depend on hiring to secure research expertise.
In 2022, federal research grants paid wages for about 122,500 people at universities that shared data with my institute. More than half of them were students or trainees. Our data shows that they go on to many types of jobs but are particularly important for leading tech companies such as Google, Amazon, Apple, Facebook and Intel.
That same data lets me estimate that over 300,000 people who worked at U.S. universities in 2022 were paid by federal research funds. Threats to federal research investments put academic jobs at risk. They also hurt private sector innovation because even the most successful companies need to hire people with expert research skills. Most people learn those skills by working on university research projects, and most of those projects are federally funded.
High stakes
If Congress doesn’t move to fund fundamental science research to meet CHIPS and Science Act targets – and make up for the $11.6 billion it’s already behind schedule – the long-term consequences for American competitiveness could be serious.
Over time, companies would see fewer skilled job candidates, and academic and corporate researchers would produce fewer discoveries. Fewer high-tech startups would mean slower economic growth. America would become less competitive in the age of AI. This would turn one of the fears that led lawmakers to pass the CHIPS and Science Act into a reality.
Ultimately, it’s up to lawmakers to decide whether to fulfill their promise to invest more in the research that supports jobs across the economy and in American innovation, competitiveness and economic growth. So far, that promise is looking pretty fragile.
Jason Owen-Smith receives research support from the National Science Foundation, the National Institutes of Health, the Alfred P. Sloan Foundation and Wellcome Leap.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
